Apyx Medical raises $9.4M in stock offering at $3.62 per share
Apyx Medical Corporation entered into an underwriting agreement with Lucid Capital Markets to complete a public offering of its common stock.
Rhea-AI Filing Summary
Apyx Medical Corporation entered into an underwriting agreement with Lucid Capital Markets to complete a public offering of its common stock. The Company issued 2,762,431 shares at an offering price of $3.62 per share and granted the underwriter an option to purchase up to an additional 414,365 shares. The offering closed on November 19, 2025, generating approximately $9.4 million in aggregate gross proceeds after a 6.0% underwriting discount and before expenses.
The Company plans to use the net proceeds for working capital and general corporate purposes, including expanding sales and marketing, capital expenditures, potential acquisitions of complementary businesses, products or technologies, and repayment of indebtedness it may incur. The transaction was conducted under an existing Form S-3 shelf registration, and customary legal opinions and underwriting documents were filed as exhibits.
Positive
- None.
Negative
- None.
Insights
Apyx raises about $9.4M via a follow-on stock sale.
Apyx Medical completed a marketed equity offering of 2,762,431 common shares at $3.62 per share, with an underwriter option for up to 414,365 additional shares. Aggregate gross proceeds are about $9.4M after a 6% underwriting discount, which increases the Company’s cash but also adds new shares to the float.
The Company states it will use net proceeds for working capital and general corporate purposes, including expanding sales and marketing, funding capital expenditures, pursuing acquisitions of complementary businesses, products or technologies, and repaying indebtedness it may incur. These stated uses suggest flexibility across growth initiatives and balance sheet support without prioritizing any single category.
Because the offering was made under an existing Form S-3 shelf and closed on November 19, 2025, execution risk on this transaction is largely removed. Future periodic filings may show how much of the funds are ultimately directed to growth investments versus debt repayment, which will shape how investors interpret the economic effect of this capital raise.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Apyx Medical (APYX) announce in this Form 8-K?
How much money did Apyx Medical (APYX) raise in the stock offering?
What will Apyx Medical (APYX) use the offering proceeds for?
When did Apyx Medical (APYX) close the offering?
Under which registration statement was the Apyx Medical (APYX) offering made?
Who acted as underwriter for the Apyx Medical (APYX) offering?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, zip code)
(
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01. | Entry into a Material Definitive Agreement. |
On November 18, 2025, Apyx Medical Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lucid Capital Markets, LLC (the “Underwriter”) pursuant to which the Company will issue and sell to the Underwriter pursuant to the Underwriting Agreement 2,762,431 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) at an offering price of $3.62 and grant to the Underwriter an option for the issuance and sale of up to 414,365 additional Shares (the “Option”) to be sold by the Company (the “Offering”).
The Offering closed on November 19, 2025. The aggregate gross proceeds to the Company from the Offering will be approximately $9.4 million, after deducting an underwriting discount of 6.0% of the price to the public, but before deducting expenses payable by the Company in connection with the Offering.
The Company expects to use the net proceeds from the Offering for working capital and general corporate purposes, including expanding its sales and marketing, capital expenditures, acquisitions of complementary businesses, products, or technologies and repaying indebtedness it may incur from time to time.
The Underwriting Agreement contains customary representations, warranties and agreements by the Company and the Underwriter, customary conditions to closing, and customary indemnification obligations of the Company.
The issuance of the Shares were made pursuant to a prospectus supplement to a Registration Statement on Form S-3 (File No. 333-268532), which was filed with the Securities and Exchange Commission (the “SEC”) on November 22, 2022 and declared effective by the SEC on December 2, 2022.
The Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. The description of the terms of the Underwriting Agreement set forth above is qualified in its entirety by reference to the full text of the Underwriting Agreement.
A copy of the legal opinion, including the related consent, of Ruskin Moscou Faltischek, P.C. relating to the legality of the issuance and sale of Shares is filed as Exhibit 5.1 to this Current Report on Form 8-K.
| Item 8.01. | Other Events. |
On November 17, 2025, the Company issued a press release announcing the launch of the Offering, and on November 18, 2025, the Company issued a press release announcing the pricing of the Offering. The launch and pricing press releases are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. | Description | |
| 1.1 | Underwriting Agreement between Company and Lucid Capital Markets, LLC, dated November 18, 2025. | |
| 5.1 | Opinion of Ruskin Moscou Faltischek, P.C. | |
| 23.1 | Consent of Ruskin Moscou Faltischek, P.C. (included in Exhibit 5.1). | |
| 99.1 | Launch Press Release, dated November 17, 2025. | |
| 99.2 | Pricing Press Release, dated November 18, 2025. | |
| 104 | Cover Page Interactive Data File embedded within the Inline XBRL document |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| APYX MEDICAL CORPORATION | ||
| Date: November 19, 2025 | By: | /s/ Matthew Hill |
| Name: | Matthew Hill | |
| Title: | Chief Financial Officer, Secretary and Treasurer | |